CSBio CSBio

X
[{"orgOrder":0,"company":"Softigel Procaps","sponsor":"SciSparc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciSparc Engages Procaps for Development and Production of CannAmide\u2122 and its SCI-110 Product Candidate","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"COLOMBIA","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Softigel Procaps"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            SCI-110 is an innovative proprietary combination drug candidate, formulated to treat the symptoms related to diseases of the central nervous system.

            Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide

            Therapeutic Area: Psychiatry/Psychology Product Name: SCI-110

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: SciSparc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 10, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY